Amarin Corporation PLC: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über Amarin Corporation PLC Unternehmen

Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

Amarin Corporation PLC Informationen



BörsenkürzelAMRN

Name des UnternehmensAmarin Corporation PLC

IPO-datumApr 01, 1993

CEOBerg (Aaron D)

Anzahl der mitarbeiter275

WertpapierartDepository Receipt

GeschäftsjahresendeApr 01

AddresseWeWork One Central Plaza Dame Street

StadtDUBLIN

BörseNASDAQ OMX - NASDAQ BASIC

LandIreland

PostleitzahlD02 K7K5

Telefon35316699020

Websitehttps://amarincorp.com/

BörsenkürzelAMRN

IPO-datumApr 01, 1993

CEOBerg (Aaron D)

Führungskräfte von Amarin Corporation PLC



Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. David Keenan, Ph.D.

Chief Operating Officer, Executive Vice President

11.71K

+3758.00%

Dr. Paul Cohen, M.D.

Non-Executive Independent Director

401.00

+401.00%

Ms. Diane E. Sullivan

Non-Executive Independent Director

401.00

+401.00%

Mr. Oliver O'Connor

Non-Executive Independent Director

401.00

+401.00%

Dr. Stephen B. (Steven) Ketchum, Ph.D.

President - Research and Development, Executive Vice President, Chief Scientific Officer

--

Mr. Aaron D. Berg

President, Chief Executive Officer, Director

--

Ms. Patrice Bonfiglio

Non-Executive Independent Director

--

Mr. Keith L. Horn

Non-Executive Independent Director

--

Dr. Odysseas D. Kostas, M.D.

Non-Executive Independent Chairman of the Board

--

Mr. Louis Sterling, III

Non-Executive Independent Director

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. David Keenan, Ph.D.

Chief Operating Officer, Executive Vice President

11.71K

+3758.00%

Dr. Paul Cohen, M.D.

Non-Executive Independent Director

401.00

+401.00%

Ms. Diane E. Sullivan

Non-Executive Independent Director

401.00

+401.00%

Mr. Oliver O'Connor

Non-Executive Independent Director

401.00

+401.00%

Dr. Stephen B. (Steven) Ketchum, Ph.D.

President - Research and Development, Executive Vice President, Chief Scientific Officer

--

Mr. Aaron D. Berg

President, Chief Executive Officer, Director

--

Umsatzaufteilung

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Nach Geschäftsbereich

Nach Region

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Aktionärsstatistik

Aktualisiert: Sun, Nov 16

Aktionäre

Aktionärstypen

Aktionäre

Anteil

Sarissa Capital Management, L.P.

5.98%

Kynam Capital Management LP

2.77%

Acadian Asset Management LLC

2.20%

Morgan Stanley & Co. LLC

1.21%

Eversept Partners, LP

0.80%

Andere

87.04%

Aktionäre

Anteil

Sarissa Capital Management, L.P.

5.98%

Kynam Capital Management LP

2.77%

Acadian Asset Management LLC

2.20%

Morgan Stanley & Co. LLC

1.21%

Eversept Partners, LP

0.80%

Andere

87.04%

Aktionärstypen

Aktionäre

Anteil

Hedge Fund

12.07%

Investment Advisor

3.02%

Investment Advisor/Hedge Fund

2.88%

Research Firm

1.93%

Individual Investor

1.05%

Pension Fund

0.30%

Family Office

0.24%

Andere

78.52%

Institutionelle Beteiligung



Aktualisiert: Mon, Dec 8

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q4

291

4.18M

22.49%

+4.06K

2025Q3

314

4.20M

24.13%

+467.66K

2025Q2

330

3.80M

23.58%

+94.36K

2025Q1

338

3.76M

23.88%

-1.19M

2024Q4

355

3.75M

23.57%

+236.09K

2024Q3

360

3.51M

29.65%

-554.68K

2024Q2

386

4.06M

34.43%

-548.92K

2024Q1

399

4.62M

36.64%

-2.90M

2023Q4

416

4.89M

38.80%

+197.93K

2023Q3

435

4.67M

42.33%

-650.41K

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

Sarissa Capital Management, L.P.

1.24M

5.98%

--

Sep 30, 2025

Kynam Capital Management LP

576.11K

2.77%

--

Sep 30, 2025

Acadian Asset Management LLC

456.58K

2.2%

+215.53K

+89.41%

Sep 30, 2025

Morgan Stanley & Co. LLC

251.41K

1.21%

+104.14K

+70.72%

Sep 30, 2025

Eversept Partners, LP

167.28K

0.8%

--

Sep 30, 2025

WaterFront Wealth, Inc.

77.96K

0.37%

-16.77K

-17.70%

Sep 30, 2025

Millennium Management LLC

132.39K

0.64%

+87.15K

+192.62%

Sep 30, 2025

Citadel Advisors LLC

122.29K

0.59%

+76.83K

+169.03%

Sep 30, 2025

SCP Investment, LP

100.00K

0.48%

-25.00K

-20.00%

Sep 30, 2025

BNP Paribas Securities Corp. North America

87.37K

0.42%

+11.43K

+15.04%

Sep 30, 2025

Verbundene ETFs



Aktualisiert: Sat, Dec 6

Name

Anteil

ProShares Ultra Nasdaq Biotechnology

0.04%

Invesco Nasdaq Biotechnology ETF

0.03%

SPDR S&P International Small Cap ETF

0.02%

Global X Aging Population ETF

0%

ActivePassive International Equity ETF

0%

Invesco NASDAQ Future Gen 200 ETF

0%

SPDR Portfolio Developed World ex-US ETF

0%

ProShares Ultra Nasdaq Biotechnology

Anteil0.04%

Invesco Nasdaq Biotechnology ETF

Anteil0.03%

SPDR S&P International Small Cap ETF

Anteil0.02%

Global X Aging Population ETF

Anteil0%

ActivePassive International Equity ETF

Anteil0%

Invesco NASDAQ Future Gen 200 ETF

Anteil0%

SPDR Portfolio Developed World ex-US ETF

Anteil0%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Ex-Dividendentag

Art

Verhältnis

Mar 12, 2025

Merger

20→1

Mar 12, 2025

Merger

20→1

Datum

Ex-Dividendentag

Art

Verhältnis

Mar 12, 2025

Merger

20→1

Mar 12, 2025

Merger

20→1